International Alzheimer’s clinical trial to test two drugs in combination

Trial participant Rachel Habiger meets in 2018 with Randall J. Bateman, MD, the director of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University School of Medicine in St. Louis. The DIAN-TU has announced that it will be targeting two key Alzheimer’s proteins — amyloid and tau — as part of its Tau Next Generation Alzheimer’s prevention trial.
View Content

Researchers leading a worldwide clinical trial aimed at finding treatments for Alzheimer’s disease are modifying an arm of the trial to evaluate a combination of drugs targeting two brain proteins: amyloid and tau. The trial – known as the Tau Next Generation Trial (Tau NexGen) – originally was announced with a focus on drugs that target tau, but with increasing evidence that targeting amyloid can reduce biomarkers of Alzheimer’s disease, the trial’s leaders have revised the first arm to include an experimental therapy targeting amyloid as well.